Updated Insights on EGFR Signaling Pathways in Glioma

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

(2020) David A. Reardon et al.   CLINICAL CANCER RESEARCH

Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report

(2020) Terri S Armstrong et al.   LANCET ONCOLOGY

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma

(2020) Nina Struve et al.   ONCOGENE

Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis

(2020) Akriti Kharbanda et al.   Science Signaling

Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways

(2020) Xiangqi Meng et al.   Nature Communications

Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation

(2020) Sylwia Jones et al.   Scientific Reports

Tackling the Many Facets of Glioblastoma Heterogeneity

(2020) Itay Tirosh et al.   Cell Stem Cell

CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells

(2020) Yingxiao Cao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses

(2020) Quazim A. Alayo et al.   Scientific Reports

Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments

(2020) Vilashini Rajaratnam et al.   Cancers

CCR5-Mediated Signaling is Involved in Invasion of Glioblastoma Cells in Its Microenvironment

(2020) Metka Novak et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme

(2020) Jason M Warram et al.   MOLECULAR CANCER THERAPEUTICS

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab®

(2020) Justyna Jureczek et al.   OncoTargets and Therapy

Efficacy of osimertinib against EGFRvIII+ glioblastoma

(2020) Gustavo Chagoya et al.   Oncotarget

Drug Conjugates for Targeting Eph Receptors in Glioblastoma

(2020) Puja Sharma et al.   Pharmaceuticals

HGF/MET Signaling in Malignant Brain Tumors

(2020) Elizabeth Qian Xu Mulcahy et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro

(2020) Cristina Horescu et al.   JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma

(2019) Christopher T. Petersen et al.   Frontiers in Oncology

Properties of FDA-approved small molecule protein kinase inhibitors

(2019) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

(2019) Pietro Paolo Vitiello et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Emerging allosteric mechanism of EGFR activation in physiological and pathological contexts

(2019) Chung-Jung Tsai et al.   BIOPHYSICAL JOURNAL

Outcome differences between first and second-generation EGFR inhibitors in advanced EGFR mutated NSCLC in a large population-based cohort

(2019) Sally C. Lau et al.   Clinical Lung Cancer

The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation

(2019) Hamza Saleem et al.   DRUG RESISTANCE UPDATES

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

(2019) Xuejiao Liu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope

(2019) Laura Orellana et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach

(2019) Teilo H. Schaller et al.   JOURNAL OF PROTEOME RESEARCH

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

(2019) Ping-Chih Hsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines

(2019) Oana Alexandru et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases

(2019) Ani-Simona Sevastre et al.   Coatings

Rethink of EGFR in Cancer With Its Kinase Independent Function on Board

(2019) Rintu Thomas et al.   Frontiers in Oncology

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets

(2019) Olivia G. Taylor et al.   Frontiers in Oncology

Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker

(2019) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

(2019) Cheila Brito et al.   BMC CANCER

Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma

(2019) Chengkun Ye et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

(2019) Fadi Jacob et al.   CELL

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma

(2019) Lisandra Muñoz-Hidalgo et al.   NEOPLASIA

The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma

(2018) Oana Alexandru et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas

(2018) A. Courtenay Freeman et al.   JOURNAL OF NEURO-ONCOLOGY

Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development

(2018) Tomoyuki Koga et al.   NEURO-ONCOLOGY

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

(2018) Zhenyi An et al.   ONCOGENE

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma

(2018) Ayguen Sahin et al.   PLoS One

Immobilization of Photo-Immunoconjugates on Nanoparticles Leads to Enhanced Light-Activated Biological Effects

(2018) Huang-Chiao Huang et al.   Small

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma

(2018) Davide Valentini et al.   Oncotarget

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

(2018) Shayna Stein et al.   PLoS Computational Biology

Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma

(2018) David C. Binder et al.   Translational Cancer Research

Dacomitinib: an investigational drug for the treatment of glioblastoma

(2018) Juan Manuel Sepúlveda et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

(2018) Quinn T Ostrom et al.   NEURO-ONCOLOGY

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

(2018) Francesco Schettini et al.   Frontiers in Oncology

Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles

(2017) Jolene Read et al.   EUROPEAN JOURNAL OF CANCER

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

(2017) Toshimitsu Yamaoka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers

(2017) Helena A. Yu et al.   LUNG CANCER

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

(2017) Hua-fu Zhao et al.   Molecular Cancer

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

(2017) Juan Manuel Sepúlveda-Sánchez et al.   NEURO-ONCOLOGY

EGFRvIII vaccine in glioblastoma—InACT-IVe or not ReACTive enough?

(2017) Michael Platten   NEURO-ONCOLOGY

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

(2017) Eskil Eskilsson et al.   NEURO-ONCOLOGY

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System

(2016) Steven J. Forrester et al.   Annual Review of Pharmacology and Toxicology

Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity

(2016) F. Ricklefs et al.   CANCER RESEARCH

Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas

(2016) P. R. Lowenstein et al.   CLINICAL CANCER RESEARCH

Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art

(2016) Reatul Karim et al.   JOURNAL OF CONTROLLED RELEASE

Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010

(2016) Adah S. Zhang et al.   NEURO-ONCOLOGY

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

(2016) Sizhi P. Gao et al.   Science Signaling

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

(2016) Sizhi P. Gao et al.   Science Signaling

PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response

(2015) Hsin-Wei Liao et al.   JOURNAL OF CLINICAL INVESTIGATION

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

(2015) J. J. Raizer et al.   JOURNAL OF NEURO-ONCOLOGY

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme

(2015) Sang-Soo Kim et al.   Nanomedicine-Nanotechnology Biology and Medicine

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

(2015) J. Schuster et al.   NEURO-ONCOLOGY

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

(2015) Emily Padfield et al.   Frontiers in Oncology

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

(2014) D. A. Reardon et al.   NEURO-ONCOLOGY

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

(2014) P. Y. Wen et al.   NEURO-ONCOLOGY

Extracellular Vesicles Modulate the Glioblastoma Microenvironment via a Tumor Suppression Signaling Network Directed by miR-1

(2013) A. Bronisz et al.   CANCER RESEARCH

Architecture and Membrane Interactions of the EGF Receptor

(2013) Anton Arkhipov et al.   CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

(2013) D. A. Reardon et al.   CLINICAL CANCER RESEARCH

The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease

(2013) Nader Makki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study

(2013) Kuo-Chen Wei et al.   PLoS One

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

(2013) David A. Nathanson et al.   SCIENCE

Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging

(2013) Xiaohui Liu et al.   Scientific Reports

Erlotinib in Glioblastoma - Lost in Translation?

(2012) Georg Karpel-Massler et al.   Anti-Cancer Agents in Medicinal Chemistry

Targeting oncogenic Ras signaling in hematologic malignancies

(2012) A. F. Ward et al.   BLOOD

Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets

(2012) Hua Mao et al.   CANCER INVESTIGATION

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

(2012) Arnab Chakravarti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

(2012) T. N. Kreisl et al.   NEURO-ONCOLOGY

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Docking proteins

(2010) Tilman Brummer et al.   FEBS Journal

MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor

(2010) Terrance G. Johns et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

(2010) Joon H. Uhm et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Constitutive Activity of Epidermal Growth Factor Receptor vIII Leads to Activation and Differential Trafficking of Wild-type Epidermal Growth Factor Receptor and erbB2

(2010) Reema Zeineldin et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Helianthin induces antiproliferative effect on human glioblastoma cells in vitro

(2010) Oana Alexandru et al.   JOURNAL OF NEURO-ONCOLOGY

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tyrosine phosphorylation: thirty years and counting

(2009) Tony Hunter   CURRENT OPINION IN CELL BIOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Oncogenic EGFR Signaling Networks in Glioma

(2009) P. H. Huang et al.   Science Signaling

Structure-Based View of Epidermal Growth Factor Receptor Regulation

(2008) Kathryn M. Ferguson   Annual Review of Biophysics

Growth factor receptors signaling in glioblastoma cells: therapeutic implications

(2008) Mia Carapancea et al.   JOURNAL OF NEURO-ONCOLOGY

Communications of the European Neurological Society

(2008)   JOURNAL OF NEUROLOGY